Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials
Dec 13, 2022
1:06:51
Episode Description
Dr. Elie Naddaf, MD interviews Dr. James Howard, MD about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis, highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
Listen On
